Literature DB >> 31312678

Preoperative Evaluation and Management of Patients Receiving Biologic Therapies.

Zahra Rezaieyazdi1,2, Maryam Sahebari1,2, Mandana Khodashahi1,2.   

Abstract

The preoperative care of patients undergoing orthopedic surgery and treated with biologic agents is of great significance. Perioperative use of biologic agents could lead to such complications as infection and delayed postoperative wound healing. This narrative review aimed to evaluate the current information on the use of biologic agents in patients undergoing orthopedic surgery, determine the rate of associated postoperative complications, and identify the appropriate time for the continuation or discontinuation of biologic therapy in these patients. It can be stated that all biologic agents increase the risk of infections depending on their half-lives. Biologic agents are suggested to be withheld for at least twice their half-lives before major surgeries. However, in case of minor operations, they can be continued given the low risk of infection and impaired wound healing in these cases. LEVEL OF EVIDENCE: I.

Entities:  

Keywords:  B cell inhibitor; Biologic therapy; Preoperative care; T cell inhibitor; TNF-α inhibitor

Year:  2019        PMID: 31312678      PMCID: PMC6578481     

Source DB:  PubMed          Journal:  Arch Bone Jt Surg        ISSN: 2345-461X


  52 in total

1.  Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001).

Authors:  J Ledingham; C Deighton
Journal:  Rheumatology (Oxford)       Date:  2005-01-05       Impact factor: 7.580

2.  Tumour necrosis factor alpha antagonists and early postoperative complications in patients with inflammatory joint disease undergoing elective orthopaedic surgery.

Authors:  S C Talwalkar; D M Grennan; J Gray; P Johnson; M J Hayton
Journal:  Ann Rheum Dis       Date:  2005-04       Impact factor: 19.103

3.  Anti-TNF alpha therapy and safety monitoring. Clinical tool guide elaborated by the Club Rhumatismes et Inflammations (CRI), section of the French Society of Rheumatology (Société Française de Rhumatologie, SFR).

Authors:  Thao Pham; Pascal Claudepierre; Xavier Deprez; Bruno Fautrel; Philippe Goupille; Pascal Hilliquin; Charles Masson; Jacques Morel; Xavier Puéchal; Alain Saraux; Thierry Schaeverbeke; Xavier Mariette; Jean Sibilia
Journal:  Joint Bone Spine       Date:  2005-06       Impact factor: 4.929

4.  Surgery in patients receiving anti-tumour necrosis factor alpha treatment in rheumatoid arthritis: an observational study on 50 surgical procedures.

Authors:  D Wendling; J-C Balblanc; A Brousse; A Lohse; G Lehuede; P Garbuio; E Toussirot; B Auge; D Jacques
Journal:  Ann Rheum Dis       Date:  2005-09       Impact factor: 19.103

Review 5.  Antibody-targeted immunotherapy for treatment of malignancy.

Authors:  C A White; R L Weaver; A J Grillo-López
Journal:  Annu Rev Med       Date:  2001       Impact factor: 13.739

Review 6.  Clinical pharmacokinetics of TNF antagonists: how do they differ?

Authors:  Ivan Nestorov
Journal:  Semin Arthritis Rheum       Date:  2005-04       Impact factor: 5.532

7.  Infectious and healing complications after elective orthopaedic foot and ankle surgery during tumor necrosis factor-alpha inhibition therapy.

Authors:  Christopher Bibbo; Jerry W Goldberg
Journal:  Foot Ankle Int       Date:  2004-05       Impact factor: 2.827

8.  Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study.

Authors:  Michele F Doran; Cynthia S Crowson; Gregory R Pond; W Michael O'Fallon; Sherine E Gabriel
Journal:  Arthritis Rheum       Date:  2002-09

9.  Antithrombotic activity of TNF-alpha.

Authors:  Beatrice Cambien; Wolfgang Bergmeier; Simin Saffaripour; Heather A Mitchell; Denisa D Wagner
Journal:  J Clin Invest       Date:  2003-11       Impact factor: 14.808

10.  Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis.

Authors:  Geraldine Cambridge; Maria J Leandro; Jonathan C W Edwards; Michael R Ehrenstein; Martin Salden; Mark Bodman-Smith; Anthony D B Webster
Journal:  Arthritis Rheum       Date:  2003-08
View more
  1 in total

Review 1.  Guidance for Administering Biologics for Severe Asthma and Allergic Conditions.

Authors:  Delbert R Dorscheid; Jason K Lee; Warren Ramesh; Mark Greenwald; Jaime Del Carpio
Journal:  Can Respir J       Date:  2022-09-10       Impact factor: 2.130

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.